AN OPEN-LABEL, RANDOMIZED PHASE 3 STUDY OF INOTUZUMAB OZOGAMICIN COMPARED TO A DEFINED INVESTIGATOR'S CHOICE IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY CD22-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL)
AN OPEN-LABEL, RANDOMIZED PHASE 3 STUDY OF INOTUZUMAB OZOGAMICIN COMPARED TO A DEFINED INVESTIGATOR'S CHOICE IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY CD22-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL)
This study will compare the efficacy, in terms of complete responses and overall survival, of inotuzumab ozogamicin versus investigator's choice of chemotherapy.
Inclusion Criteria:
Exclusion Criteria:
La Jolla, California 92037-0845, United States
Los Angeles, California 90027, United States
Los Angeles, California 90033, United States
Palo Alto, California 94304, United States
Stanford, California 94305, United States
Orlando, Florida 32806, United States
Augusta, Georgia 30912, United States
Farmington Hills, Michigan 48334, United States
Hackensack, New Jersey 07601, United States
Albuquerque, New Mexico 87131-0001, United States
New York, New York 10065, United States
Stony Brook, New York 11794-9447, United States
Stony Brook, New York 11794, United States
Chapel Hill, North Carolina 27599-7600, United States
Hershey, Pennsylvania 17033, United States
Dallas, Texas 75390, United States
Morgantown, West Virginia 26506, United States
Tianjin, 300020, China
Debrecen, 4032, Hungary
Cona, Ferrara, 44124, Italy
Nishinomiya-shi, Hyōgo 6638501, Japan
Chuo-ku, Tokyo 1040045, Japan
Lodz, 93510, Poland
Wroclaw, 53-439, Poland
Singapore, 119228, Singapore
Hwasun-Gun, Jeollanam-do 519-763, South Korea